SCHEMBL299324

SCHEMBL299324

C=CCOCC[N+](C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
CHRM5 P08912 6/20 0.34
CHRM1 P11229 6/20 0.34
CHRM3 P20309 6/20 0.34
CHRM2 P08172 5/20 0.34
CHRM4 P08173 5/20 0.34
CHRNB2 P17787 4/20 0.34
CHRNA4 P43681 4/20 0.34
CHRNA7 P36544 3/20 0.34
HTR1A P08908 2/20 0.34
ADRA2A P08913 1/20 0.34
ADRA1A P35348 1/20 0.34
PGR P06401 1/20 0.34
TBXA2R P21731 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CHRNA10 Q9GZZ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5936905 0.98 MEN1 (0.43) MEN1POLBKMT2ACHRM5CHRM1
Hydrochloric Acid SCHEMBL9193442 0.98 MEN1 (0.43) MEN1POLBKMT2ACHRM5CHRM1
Phosphoric Acid SCHEMBL3447199 0.88 LMNA (0.42) MEN1POLBKMT2ACHRM5CHRM1
Phosphonic Acid SCHEMBL28825299 0.88 MEN1 (0.37) MEN1POLBKMT2ACHRM5CHRM1
SCHEMBL83823 0.86 MEN1 (0.42) MEN1POLBKMT2ASMN1; SMN2LMNA
SCHEMBL327528 0.85 MEN1 (0.45) MEN1POLBKMT2ACA1CA2
SCHEMBL327742 0.85 MEN1 (0.45) MEN1POLBKMT2ACA1CA2
Phosphoric Acid SCHEMBL3446695 0.84 SMN1; SMN2 (0.37) MEN1POLBKMT2ACHRM5CHRM1
Hydrochloric Acid SCHEMBL9280456 0.83 MEN1 (0.43) MEN1POLBKMT2ACA1CA2
Bromide SCHEMBL1955038 0.83 MEN1 (0.43) MEN1POLBKMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3600380-A1 ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES Rezolute, Inc. (US) 2020-02-05 EP claimed
CN-110662550-A Oral administration of physiologically active substances 瑞泽路特有限公司 2020-01-07 CN claimed
US-20180271792-A1 ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES REZOLUTE, INC. (US) 2018-09-27 US claimed
WO-2018175250-A1 ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES REZOLUTE, INC. (US) 2018-09-27 WO claimed
WO-2016156559-A1 CLAY STABILIZING COMPOSITIONS AND USE OF SAID COMPOSITIONS FOR STABILIZING WATER SENSITIVE FORMATIONS TAMINCO BVBA (BE) 2016-10-06 WO claimed
CN-1451004-A 7-oxopyridopyrimidines HOFFMANN LA ROCHE (CH) 2003-10-22 CN claimed
EP-4536612-A1 COMPOSITION COMPRISING A EUTECTIC MIXTURE COMPRISING AN ALKYLTHIOPHOSPHORIC TRIAMIDE UREASE INHIBITOR SPECIALTY OPERATIONS FRANCE (FR) 2025-04-16 EP disclosed
CN-118202067-A Nucleic acid amplification promoter and inspection method using the same 日油株式会社 2024-06-14 CN disclosed
WO-2023237755-A1 COMPOSITION COMPRISING A EUTECTIC MIXTURE COMPRISING AN ALKYLTHIOPHOSPHORIC TRIAMIDE UREASE INHIBITOR SPECIALTY OPERATIONS FRANCE (FR) 2023-12-14 WO disclosed
US-11680946-B1 Detection of cholinesterase inhibition with microfluidic devices and systems thereof NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2023-06-20 US disclosed
US-20210023009-A1 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY BEN GURION UNIV OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2021-01-28 US disclosed
US-10842747-B2 Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery Ben-Gurion University of Negev R & D (IL) 2020-11-24 US disclosed
CN-107507999-B Electrolyte composition and metal ion battery comprising same 财团法人工业技术研究院 2019-11-08 CN disclosed
CN-103113242-A Functional choline chloride ionic liquid and preparation method and application in electrochemical energy storage device thereof GUANGZHOU INST ENERGY CONV CAS 2013-05-22 CN disclosed
US-20120164072-A1 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2012-06-28 US disclosed
EP-2427175-A2 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY Ben-gurion University Of The Negev Research And Development Authority (IL) 2012-03-14 EP disclosed
WO-2010128504-A2 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2010-11-11 WO disclosed
CN-101475585-A New compound alkyl bilineurine phosphodiester (miltefosine)and preparation YONGGANG WEI (CN) 2009-07-08 CN disclosed
CN-100376516-C Sulphonylation method and reagent useful for perhalogenated sulphanilide synthesis RNODIA CHIMIE (FR) 2008-03-26 CN disclosed
CN-1325371-A Sulfonylation method and reagent for synthesis of perhalogenated sulphanilide RNODIA CHIMIE (FR) 2001-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120164072-A1 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY TSPO, ANXA6, ANXA11 MEN1 334/4885POLB 3423/4885KMT2A 3066/4885
US-20210023009-A1 NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY TSPO, ANXA6, ANXA11 MEN1 334/4885POLB 3423/4885KMT2A 3066/4885
US-10842747-B2 Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery TSPO, ANXA6, ANXA11 MEN1 334/4885POLB 3423/4885KMT2A 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.